Paper · 38643262
TMAO enhances TNF-α mediated fibrosis and release of inflammatory mediators from renal fibroblasts.
Stefania K and 4 others. Sci Rep, 2024. Cited by 38 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. TMAO enhances TNF-α mediated fibrosis and release of inflammatory mediators from renal fibroblasts. Papers, record 38643262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38643262
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TMAO enhances TNF-α mediated fibrosis and release of inflammatory mediators from renal fibroblasts.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Tumor Necrosis Factor-alpha | Major topic |
| Renal Insufficiency, Chronic | Major topic |
| Methylamines | Major topic |
| Humans | |
| Inflammation Mediators | |
| Fibrosis | |
| Cytokines | |
| Fibroblasts | |
| Inflammation | |
| Collagen |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,436,815 | Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. | Sci Rep | 2021 | https://conductscience.org/library/papers/33436815 | PubMed |
| 2 | 35,729,842 | The role of IL-10 in kidney disease. | Int Immunopharmacol | 2022 | https://conductscience.org/library/papers/35729842 | PubMed |
| 3 | 22,009,250 | Cellular and molecular mechanisms of renal fibrosis. | Nat Rev Nephrol | 2011 | https://conductscience.org/library/papers/22009250 | PubMed |
| 4 | 34,769,294 | The Fibrotic Effects of TMAO on Human Renal Fibroblasts Is Mediated by NLRP3, Caspase-1 and the PERK/Akt/mTOR Pathway. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34769294 | PubMed |
| 5 | 36,195,887 | TNFα and IFNγ rapidly activate PI3K-AKT signaling to drive glycolysis that confers mesenchymal stem cells enhanced anti-inflammatory property. | Stem Cell Res Ther | 2022 | https://conductscience.org/library/papers/36195887 | PubMed |
| 6 | 18,508,599 | Urokinase and its receptors in chronic kidney disease. | Front Biosci | 2008 | https://conductscience.org/library/papers/18508599 | PubMed |
| 7 | 16,951,369 | Distinct in vivo roles of colony-stimulating factor-1 isoforms in renal inflammation. | J Immunol | 2006 | https://conductscience.org/library/papers/16951369 | PubMed |
| 8 | 7,773,632 | Human renal fibroblast cell lines (tFKIF and tNKF) are new tools to investigate pathophysiologic mechanisms of renal interstitial fibrosis. | Exp Nephrol | 1995 | https://conductscience.org/library/papers/7773632 | PubMed |
| 9 | 20,502,043 | The role of tubulointerstitial inflammation in the progression of chronic renal failure. | Nephron Clin Pract | 2010 | https://conductscience.org/library/papers/20502043 | PubMed |
| 10 | 32,365,994 | The Role of Wnt Signalling in Chronic Kidney Disease (CKD). | Genes (Basel) | 2020 | https://conductscience.org/library/papers/32365994 | PubMed |
1 to 10 of 61
See all 61 referencesCited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,589,363 | Intestinal Flora and Myocarditis: Potential Mechanisms and Therapeutic Strategies Affecting Disease Progression and Cardiac Function. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42589363 | PubMed |
| 42,495,760 | Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review). | Int J Mol Med | 2026 | https://conductscience.org/library/papers/42495760 | PubMed |
| 42,239,940 | Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease. | Diabetes Metab Syndr Obes | 2026 | https://conductscience.org/library/papers/42239940 | PubMed |
| 42,008,043 | Targeting YAP: mechanistic breakthroughs and therapeutic prospects in reversing organ fibrosis. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42008043 | PubMed |
| 41,674,334 | Applying dendrimer nanoprobes to the diagnosis and evaluation of kidney fibrosis. | Nanomedicine (Lond) | 2026 | https://conductscience.org/library/papers/41674334 | PubMed |
| 41,632,330 | IFN-γ and TNF-α Impair Lung Development by Upregulating SMAD7 to Inhibit TGF-β Signaling Pathway and ECM Dysregulation. | Inflammation | 2026 | https://conductscience.org/library/papers/41632330 | PubMed |
| 41,628,781 | Gut microbiota-derived metabolites as immune modulators in aging and age-related chronic inflammatory diseases. | Ageing Res Rev | 2026 | https://conductscience.org/library/papers/41628781 | PubMed |
| 41,522,487 | The Gut Microbiota-Insulin Resistance Axis: Mechanisms, Clinical Implications, and Therapeutic Potential. | FASEB Bioadv | 2026 | https://conductscience.org/library/papers/41522487 | PubMed |
| 41,453,954 | Trimethylamine-N-oxide promotes fibrotic activation of quiescent valvular interstitial cells via endoplasmic reticulum stress. | Sci Rep | 2025 | https://conductscience.org/library/papers/41453954 | PubMed |
| 41,441,627 | Correlations Between Trimethylamine-N-Oxide, Megalin, Lysine and Markers of Tubular Damage in Chronic Kidney Disease. | Toxins (Basel) | 2025 | https://conductscience.org/library/papers/41441627 | PubMed |
1 to 10 of 30
See all 30 cited byGenes13
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CCL7 | 6,354 | PubTator's text mining | https://conductscience.org/library/genes/6354 | NCBI Gene |
| CD40 | 958 | PubTator's text mining | https://conductscience.org/library/genes/958 | NCBI Gene |
| CXCL6 | 6,372 | PubTator's text mining | https://conductscience.org/library/genes/6372 | NCBI Gene |
| FN1 | 2,335 | PubTator's text mining | https://conductscience.org/library/genes/2335 | NCBI Gene |
| HGF | 3,082 | PubTator's text mining | https://conductscience.org/library/genes/3082 | NCBI Gene |
| IL6 | 3,569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| LAP | 7,939 | PubTator's text mining | https://conductscience.org/library/genes/7939 | NCBI Gene |
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MTOR | 2,475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
1 to 10 of 13
See all 13 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38643262
GET https://conductscience.org/api/papers/v1/38643262/references?page=2